Ionis Pharmaceuticals Inc (FRA:ISI)
€ 33.48 -0.13 (-0.39%) Market Cap: 5.40 Bil Enterprise Value: 4.42 Bil PE Ratio: 0 PB Ratio: 8.55 GF Score: 60/100

Ionis Pharmaceuticals Inc at Wells Fargo Healthcare Conference Transcript

Sep 07, 2022 / 03:00PM GMT
Release Date Price: €44.5 (+2.45%)
Yanan Zhu
Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst

Okay. So thanks, everyone, for joining us. I think we should get started. We are very fortunate here to have the team from Ionis presenting at our conference. My name is Yanan, and with us today here are Brett Monia, CEO of Ionis; and Eugene Schneider, the Chief Clinical Development Officer at Ionis. So Brett and Eugene, thank you for being with us.

Brett P. Monia
Ionis Pharmaceuticals, Inc. - Founder, CEO & Director

Thank you. Thanks for having us.

Questions & Answers

Yanan Zhu
Wells Fargo Securities, LLC, Research Division - Senior Equity Analyst

So this morning, actually, the company reported the Phase III data for eplontersen in ATTR cardiomyopathy at the IFA conference in Germany. Would you -- could you walk us through the data and tell us why you're so excited about the eplontersen program?

Brett P. Monia
Ionis Pharmaceuticals, Inc. - Founder, CEO & Director

Happy

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot